Intrauterine Treatment of a Fetus with Familial Hypertrophic Cardiomyopathy Secondary to MYH7 Mutation

Pediatric Cardiology
Meghan G HillBrent J Barber

Abstract

There is no clear consensus on optimal management of fetuses affected by familial hypertrophic cardiomyopathy (HCM). Intrauterine treatment of the condition has not been attempted in any standardized fashion. We report the case of a fetus treated by maternal propranolol during the third trimester after septal hypertrophy and diastolic dysfunction was diagnosed on fetal echocardiogram. The pregnancy went successfully to term, and fetal septal hypertrophy was noted to improve prior to delivery.

References

Sep 14, 1999·Journal of the American College of Cardiology·F Alfonso, W J McKenna
Jul 31, 2002·Circulation·Simone R F F PedraLisa K Hornberger
Sep 1, 1994·Ultrasound in Obstetrics & Gynecology : the Official Journal of the International Society of Ultrasound in Obstetrics and Gynecology·K HecherK Nicolaides
Jul 17, 2012·Journal of the American College of Cardiology·Barry J MaronChristopher Semsarian

❮ Previous
Next ❯

Citations

Jan 1, 2016·Pediatric Cardiology·Edward G Abinader

❮ Previous
Next ❯

Methods Mentioned

BETA
cesarean section

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.